II类铁死亡诱导剂是治疗t(4;14)阳性多发性骨髓瘤的新方法
本研究在临床前阶段发现,t(4;14)阳性而非t(4;14)阴性的多发性骨髓瘤细胞对II类铁死亡诱导剂敏感,该敏感性依赖于MMSET蛋白上调ACSL4转录从而增加多不饱和脂肪酸水平。II类铁死亡诱导剂联合硼替佐米在体外及异种移植模型中表现出协同抗肿瘤活性。
要点
- t(4;14)阳性多发性骨髓瘤细胞对II类铁死亡诱导剂敏感,t(4;14)阴性细胞不敏感。
- MMSET通过结合ACSL4启动子上调其转录,增加多不饱和脂肪酸水平。
- II类铁死亡诱导剂联合硼替佐米在体外和异种移植模型中显示协同抗肿瘤活性。
核心结论
- 靶向铁死亡 with II类铁死亡诱导剂是改善t(4;14)阳性多发性骨髓瘤患者结局的新颖且有前景的治疗方法。
研究设计与样本
- 临床前研究,使用t(4;14)阳性和t(4;14)阴性多发性骨髓瘤细胞及异种移植模型。
主要发现
- t(4;14)阳性而非t(4;14)阴性的多发性骨髓瘤细胞对II类铁死亡诱导剂敏感,依赖于MMSET的显著上调。
- MMSET通过结合ACSL4启动子区域上调其转录,导致多不饱和脂肪酸水平增加,增强t(4;14)阳性细胞对铁死亡的敏感性。
- 补充多不饱和脂肪酸可有效恢复t(4;14)阴性多发性骨髓瘤细胞对铁死亡的敏感性。
- 在t(4;14)阳性多发性骨髓瘤细胞中,II类铁死亡诱导剂联合硼替佐米通过抑制SLC7A11的增加,降低细胞谷胱甘肽并诱导凋亡和铁死亡,在体外和异种移植模型中显示协同抗肿瘤活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a clonal plasma cell malignancy that is characterized by genetic heterogeneity. The cytogenetic abnormality t(4;14) strongly predicts poor outcome in patients with MM, even in the era of novel drugs. Ferroptosis is a new approach to antitumor therapy, but the relationship between ferroptosis and MM cytogenetic abnormalities remains largely unclear. In this study, we show that t(4;14)-positive but not t(4;14)-negative MM cells are susceptible to class II ferroptosis inducers (FINs) in a preclinical setting, which is dependent on the significant upregulation of the MM SET domain-containing protein (MMSET). Mechanistically, MMSET upregulates acyl-coenzyme A synthetase long-chain family member 4 transcription by binding to its promoter region, leading to increased polyunsaturated fatty acid (PUFA) levels and enhanced sensitivity of t(4;14)-positive MM cells to ferroptosis. Supplementation with PUFAs efficiently restores the susceptibility of t(4;14)-negative MM cells to ferroptosis. In addition, combining class II FIN treatment with bortezomib in t(4;14)-positive MM cells attenuates cellular glutathione and induces both apoptosis and ferroptosis levels by inhibiting the increase in solute carrier family 7 member 11, demonstrating synergistic antitumor activity in vitro and in a xenograft model. Taken together, our findings suggest that targeting ferroptosis with class II FINs is a novel and promising therapeutic approach to improve the outcome of t(4;14)-positive patients with MM.
引用
- Zhang J, Liu Y, Zuo L, et al. Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma. Blood Adv. 2024. PMID: 39042883. doi:10.1182/bloodadvances.2023010335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。